Jordan Clark | Authors


Discussing Reimbursement Barriers for FLT3 Mutation Analysis

July 11, 2019

FLT3 mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke to Targeted Oncology about the cause of reimbursement issues and how the problem affects all parties involved.